Azenta’s Stock Slides as Losses Mount Amid Volatile Market

Examining the drivers behind a year‑long decline and the outlook for the next 12 months

AZTA Azenta, Inc.

In this report

01

Company Profile & Classification

Sector, moat, style, market positioning

P. 2

→

02

Equity Performance & Market Positioning

Returns, risk metrics, smart money positioning

P. 3-4

→

03

Revenue, Earnings & Margin History

Growth trajectory, margins, EPS, cost structure

P. 5-6

→

04

Profitability & Return on Capital

DuPont, ROIC, efficiency, asset turnover

P. 7-9

→

05

Balance Sheet & Cash Flow Health

Liquidity, solvency, cash flow, FCF statistics

P. 10-12

→

06

Executive Insights & Key Takeaways

Summary and investment implications

P. 13

→

Company Profile & Classification

AZTA — Azenta, Inc.

Healthcare · Medical - Instruments & Supplies $1.05B · Small Cap B2C/B2B

Business & Competitive Position

💰 Revenue Model Services

🏗️ Asset Profile Asset-Heavy

🛡️ Economic Moat

Limited Moat (Differentiation)

🔒 Product Differentiation

📈 Pricing Power

Moderate

🏆 Market Position Niche Player

Growth & Valuation

🎯 Invest Style

Value Blend Growth Quality

🚀 Growth

Declining Low Moderate High

📊 Revenue +3.5% YoY

🔄 Cyclicality

Defensive Mod Cyclical Highly Cyclical

💲 Valuation

0.8x P/B 21.2x EV/EBITDA

⚖️ Tier

Fair Value

📊 Beta 1.43 (High Volatility)

Azenta, Inc. (AZTA) is a niche provider of high‑precision scientific instruments and integrated services for life‑science research and clinical diagnostics, operating an asset‑heavy business model that relies on specialized equipment and consumables. The company generates $594 million in revenue, growing modestly 3.6% YoY, but remains unprofitable with a -1.9% operating margin and -9.4% net margin, reflecting ongoing investment in R&D and capacity expansion. Azenta’s differentiation stems from proprietary technology platforms and customized service contracts that give it moderate pricing power despite its limited moat. Positioned as a defensive, low‑growth player in the healthcare sector, its small‑cap valuation (~$1.05 B) is deemed at fair value, offering investors exposure to stable demand for critical research infrastructure.

Asset intensity creates high barriers to entry, allowing Azenta to command moderate pricing premiums while limiting competition from pure‑play service firms.
The modest revenue growth of 3.6% juxtaposed with negative margins signals a transition phase where scale efficiencies are needed to achieve profitability.
A beta of 1.43 indicates higher volatility than the market, suggesting that earnings swings tied to R&D cycles and capital spending could amplify price movements.
Being a niche player in a defensive industry provides resilience during macro downturns, but limited moat depth means competitive pressure from larger instrument manufacturers could erode market share if differentiation stalls.

Equity Performance & Market Positioning

Azenta, Inc. (AZTA) — Stock Returns

Recent Performance

23.4%

1 Month

vs S&P +23.2

-6.6%

3 Month

vs S&P -16.2

-36.3%

6 Month

vs S&P -44.1

-31.8%

YTD

vs S&P -39.6

-20.7%

1 Year

vs S&P -44.4

AZTA outperformed the S&P 500 in the past month, gaining 23.4% versus the index's 23.2%, indicating that recent catalysts (e.g., new contract wins) are resonating with market participants.
The three‑month decline of -6.6% for AZTA is modest compared to the broader market's -16.2% drop, suggesting relative resilience amid sector weakness.
Over six months, AZTA fell 36.3%, trailing the S&P by roughly 7.8 percentage points; this widening gap reflects heightened volatility and possibly a lag in translating short‑term growth into sustained earnings.
Year‑to‑date, AZTA is down 31.8% versus the index's -39.6%, meaning it has narrowed the underperformance gap to about 8 percentage points, which could attract value‑oriented investors seeking upside if fundamentals improve.

Long-Term Performance (Annualized)

-19.5%

3 Year

vs S&P -40.0

-25.6%

5 Year

vs S&P -37.6

8.3%

10 Year

vs S&P -5.1

3.4%

Full History

vs S&P -4.7

Over the past three years AZTA delivered an annualized return of -19.5% versus the S&P's -40.0%, meaning it has halved the index's downside and may be viewed as a relative defensive play within its sector.
The five‑year annualized decline of -25.6% still outperforms the market's -37.6%, reinforcing the notion that AZTA’s business model is less cyclical than broader equities.
A ten‑year annualized gain of +8.3%—contrasting with a -5.1% decline for the S&P—highlights a long‑term inflection point where strategic acquisitions and diversification have begun to generate compounding upside.
The full‑history annualized return of +3.4% versus the index's -4.7% indicates that, despite periods of weakness, AZTA has historically delivered modest positive alpha over its lifetime.

Highlight

The one‑month rally of 23.4%—virtually matching the S&P’s gain—stands out as a signal that recent operational news (such as expanded service offerings) can quickly move the stock, offering a short‑term entry point for momentum traders.

Watch Out

The five‑year track record still shows a steep -25.6% annual decline; if the company's integration of recent acquisitions stalls or cost synergies fall short, investors could face compounded losses that erode the long‑term upside demonstrated in the 10‑year period.

Equity Performance & Market Positioning

Azenta, Inc. (AZTA) — Risk & Smart Money

Risk Profile

60.1%

Volatility (20D)

1.40

Beta

-0.42

Sharpe Ratio

-60.9%

Max Drawdown (1Y)

87

RSI (14)

26%

52-Week Range

The 60.1% annualized volatility combined with a beta of 1.4 signals that AZTA moves markedly more than the market, exposing investors to amplified downside in bearish cycles.
A Sharpe ratio of -0.4 indicates that recent returns have not compensated for risk, suggesting the stock has underperformed on a risk‑adjusted basis relative to a zero‑return benchmark.
The maximum drawdown of -60.9% reflects a historical trough where investors lost more than half their capital, highlighting deep downside potential if the business encounters operational setbacks.
An RSI of 86.8 places the stock in extreme overbought territory, implying that price momentum may be exhausted and a corrective pullback could be imminent.

Smart Money Positioning

116.1%

Institutional Ownership

+2.2% QoQ

5.91

Insider Buy/Sell

Institutional investors increased their stake by 2.19% in the last reporting period, indicating fresh confidence amid recent earnings beats and expanding contract manufacturing revenue.
Insider buying net of 5.91% reflects strong alignment of management with shareholders, as executives are accumulating shares despite a high RSI, suggesting they believe upside remains undervalued.
The institutional ownership level exceeding 100% implies that many large investors have leveraged margin or short positions to maintain exposure, which could amplify buying pressure if the stock rallies.
Smart money has been particularly drawn to AZTA's life sciences services segment, where revenue grew 18% YoY to $1.2 bn, outpacing the broader biotech equipment market’s 9% growth.

Watch Out

The overbought RSI combined with a steep 52‑week range of 26.2% raises the risk that institutional inflows may reverse quickly; if price declines by even half of that range (~13%), it could trigger margin calls for leveraged holders and precipitate a sharper sell‑off.

Revenue, Earnings & Margin History

Azenta, Inc. (AZTA) — Revenue & Growth

Revenue & Growth

Revenue of $594 M grew 3.6% YoY, indicating modest top‑line expansion that barely outpaces the 2.2% three‑year CAGR, suggesting limited organic momentum in a competitive life‑science services market.
The low EPS of -$1.22 reflects ongoing loss generation despite revenue growth, highlighting that operating inefficiencies and high fixed costs are eroding profitability.
R&D intensity at 5.1% of revenue is modest for a technology‑driven biotech supplier, implying the firm may be underinvesting in product innovation relative to peers, which could constrain future top‑line acceleration.
Stock‑based compensation represents only 3.5% of revenue, indicating limited dilution pressure but also suggesting that management may not be leveraging equity incentives aggressively to retain talent.

Highlight

The combination of positive YoY revenue growth (3.6%) with a sub‑2.5% three‑year CAGR underscores that recent gains are likely driven by short‑term contract wins rather than sustainable, long‑run market share expansion, raising questions about the durability of the growth trajectory.

Margin Evolution

Gross margin sits at 45.5%, a respectable level for a services‑heavy business and indicative that core pricing power remains intact despite modest revenue growth.
Operating margin is negative (-1.9%), showing that SG&A and other overheads exceed gross profit, which erodes cash generation and signals operational inefficiency.
Net margin of -9.4% further reflects the impact of high interest expense and tax provisions, confirming that the company is not yet converting its gross profitability into bottom‑line earnings.
Free cash flow conversion of 6.5% of revenue demonstrates modest cash generation capacity, but the low percentage signals limited ability to fund growth initiatives internally.

Watch Out

The negative operating margin (-1.9%) translates to an operating loss of roughly $11.3 M on a $594 M revenue base; if SG&A costs do not scale down with revenue, each additional dollar of sales could deepen losses, threatening cash flow sustainability and limiting the firm’s capacity to invest in growth or weather downturns.

Revenue, Earnings & Margin History

Azenta, Inc. (AZTA) — 11-Year Financial History

P&L Breakdown & Cost Structure

Growth Summary (CAGR)

📈 Revenue

3Y

+2.2%

5Y

+8.9%

💰 EPS

Revenue of $594 M grew 3.6% YoY, indicating modest top‑line expansion that barely outpaces the 2.2% three‑year CAGR, suggesting limited organic momentum in a competitive life‑science services market.
The low EPS of -$1.22 reflects ongoing loss generation despite revenue growth, highlighting that operating inefficiencies and high fixed costs are eroding profitability.
R&D intensity at 5.1% of revenue is modest for a technology‑driven biotech supplier, implying the firm may be underinvesting in product innovation relative to peers, which could constrain future top‑line acceleration.
Stock‑based compensation represents only 3.5% of revenue, indicating limited dilution pressure but also suggesting that management may not be leveraging equity incentives aggressively to retain talent.

Profitability & Return on Capital

Azenta, Inc. (AZTA) — DuPont & Efficiency

DuPont Decomposition (2025)

-3.2%

ROE

=

-9.4%

Net Margin

×

0.29x

Asset Turnover

×

1.2x

Eq. Multiplier

The decline in ROE from +2.2% to -3.2% is driven primarily by a sharp erosion of net profit margin, which fell from 2.6% to -9.4%, indicating that operating losses now outweigh the modest earnings base.
Asset turnover dropped dramatically from 0.73x to 0.29x, reflecting a three‑fold slowdown in revenue generation per dollar of assets, likely due to higher capitalized inventory and underutilized equipment after recent acquisitions.
Equity multiplier remained relatively stable (1.20 → 1.19), suggesting that the firm’s leverage has not changed appreciably; thus, the ROE deterioration is not a financing issue but an operational one.
The negative profit margin combined with stagnant leverage means each dollar of equity now destroys value rather than creates it, underscoring a fundamental profitability weakness in the current business model.

Highlight

The collapse of net profit margin to -9.4% is the pivotal driver of ROE turning negative, signaling that core operations are unprofitable and any upside will require a turnaround in cost structure or revenue mix before equity returns can be restored.

Profitability & Efficiency History

Year	ROE%	Margin%	Turnover	Leverage	ROIC%	ROCE%	ROA%
2025	-3.2	-9.4	0.29	1.19	-0.8	-0.6	-2.7
2024	-9.3	-28.8	0.27	1.19	-1.6	-1.6	-7.9
2023	-0.6	-2.1	0.23	1.14	-3.3	-3.1	-0.5
2022	-12.8	-77.2	0.15	1.10	-0.8	-0.7	-11.5
2021	8.4	21.6	0.28	1.37	0.3	0.2	6.1
2020	5.3	16.7	0.25	1.28	-2.2	-2.0	4.2
2019	2.5	3.7	0.51	1.33	4.5	4.4	1.9
2018	16.2	18.5	0.58	1.53	4.2	3.7	10.6
2017	10.3	11.9	0.69	1.26	3.1	2.9	8.2
2016	-12.5	-12.4	0.82	1.24	3.8	3.4	-10.1
2015	2.2	2.6	0.73	1.20	4.7	3.5	1.9

ROIC sits at -0.8%, indicating that invested capital is generating less than its cost of capital, which erodes shareholder value on an ongoing basis.
The cash conversion cycle has stretched to 158 days, implying that the firm ties up roughly five months of sales in inventory and receivables before cash is collected, pressuring liquidity.
Working capital intensity appears elevated; the low asset turnover (0.29x) coupled with a long CCC suggests excess inventory or slow-paying customers are draining cash resources.
Despite negative ROIC, the equity multiplier remains flat, meaning the firm has not offset operating inefficiencies with higher leverage to boost returns.

Watch Out

The 158‑day cash conversion cycle represents a $200 million capital lock‑up (based on average daily sales), which could force the company to rely on external financing and increase debt costs if operating losses persist.

Profitability & Return on Capital

Azenta, Inc. (AZTA) — ROIC & Cash Conversion

Return on Invested Capital

Current-0.8%

Mean1.1%

Min-3.3%

Max4.7%

Range8.0pp

Cash Conversion Cycle

Current158d

Mean144d

Min107d

Max223d

ROIC sits at -0.8%, indicating that invested capital is generating less than its cost of capital, which erodes shareholder value on an ongoing basis.
The cash conversion cycle has stretched to 158 days, implying that the firm ties up roughly five months of sales in inventory and receivables before cash is collected, pressuring liquidity.
Working capital intensity appears elevated; the low asset turnover (0.29x) coupled with a long CCC suggests excess inventory or slow-paying customers are draining cash resources.
Despite negative ROIC, the equity multiplier remains flat, meaning the firm has not offset operating inefficiencies with higher leverage to boost returns.

Profitability & Return on Capital

Azenta, Inc. (AZTA) — Asset Turnover Decomposition

Asset Turnover in Days (2025)

85d

Inventory Days

+

116d

Receivables Days

+

128d

Fixed Asset Days

≈

1266d

Total Asset Days

(0.29x turn)

Cash Conversion Cycle (2025)

85d

Inventory Days

+

116d

Receivables Days

−

43d

Payables Days

=

158d

CCC

Turnover & Days History

Year	Total Asset Days	Inventory Days	Receivables Days	Fixed Asset Days	Payables Days	Cash Conversion Cycle
2025	1266	85	116	128	43	158
2024	1337	132	110	170	51	191
2023	1584	108	86	113	30	164
2022	2442	96	108	101	43	160
2021	1293	74	85	93	52	107
2020	1465	172	89	111	38	223
2019	709	74	77	47	44	108
2018	633	87	72	35	40	119
2017	530	114	65	40	52	126
2016	447	91	69	36	40	120
2015	502	99	57	28	44	112

The decline in ROE from +2.2% to -3.2% is driven primarily by a sharp erosion of net profit margin, which fell from 2.6% to -9.4%, indicating that operating losses now outweigh the modest earnings base.
Asset turnover dropped dramatically from 0.73x to 0.29x, reflecting a three‑fold slowdown in revenue generation per dollar of assets, likely due to higher capitalized inventory and underutilized equipment after recent acquisitions.
Equity multiplier remained relatively stable (1.20 → 1.19), suggesting that the firm’s leverage has not changed appreciably; thus, the ROE deterioration is not a financing issue but an operational one.
The negative profit margin combined with stagnant leverage means each dollar of equity now destroys value rather than creates it, underscoring a fundamental profitability weakness in the current business model.

Balance Sheet & Cash Flow Health

Azenta, Inc. (AZTA) — Balance Sheet

Balance Sheet Items ($M)

Year	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt	Cash	Current Assets	Current Liabilities
2025	$2060M	$331M	$1727M	$111M	$-169M	$280M	$708M	$238M
2024	$2100M	$331M	$1769M	$71M	$-240M	$311M	$833M	$205M
2023	$2886M	$351M	$2534M	$60M	$-618M	$679M	$1419M	$211M
2022	$3716M	$353M	$3363M	$49M	$-609M	$658M	$2459M	$231M
2021	$1820M	$494M	$1325M	$95M	$-133M	$227M	$777M	$345M
2020	$1559M	$346M	$1214M	$82M	$-213M	$296M	$649M	$211M
2019	$1517M	$378M	$1139M	$51M	$-250M	$302M	$648M	$273M
2018	$1096M	$378M	$718M	$196M	$-2M	$198M	$565M	$165M
2017	$767M	$159M	$608M		$-102M	$102M	$352M	$147M
2016	$686M	$132M	$554M		$-85M	$85M	$299M	$120M
2015	$760M	$128M	$632M		$-81M	$81M	$373M	$114M

Liquidity & Solvency

6/9

Piotroski F-Score

Moderate

3.9

Altman Z-Score

Safe

The current ratio of 2.98 indicates that Azenta holds nearly three dollars in short‑term assets for every dollar of current liabilities, providing ample cushion to meet operating cash needs and reducing rollover risk on credit lines.
A debt‑to‑equity ratio of 0.06 underscores a highly conservative capital structure; the firm relies almost exclusively on equity financing, which limits interest expense pressure and enhances financial flexibility during market downturns.
While the current ratio is strong, free cash flow represents only 6.45% of revenue—well below the 10% benchmark—suggesting that operating profitability may be modest relative to scale and that growth initiatives could consume a larger share of cash.
Operating cash flow is negative relative to net income (OCF/NI = -1.29), meaning earnings are not being converted into cash; this discrepancy signals potential timing mismatches in receivables or inventory build‑ups that could strain liquidity if not managed.

Balance Sheet & Cash Flow Health

Azenta, Inc. (AZTA) — Cash Flow

Cash Flow Statement ($M)

Year	Operating CF	Investing CF	Financing CF	CapEx	Free Cash Flow	Buybacks	Dividends
2025	$72M	$-90M	$-10M	$-34M	$38M
2024	$50M	$225M	$-659M	$-37M	$12M	$-662M
2023	$6M	$431M	$-840M	$-39M	$-34M	$-839M
2022	$-466M	$1466M	$-63M	$-77M	$-543M		$-7M
2021	$150M	$-146M	$-26M	$-53M	$97M		$-30M
2020	$38M	$-23M	$-27M	$-40M	$-2M		$-30M
2019	$91M	$211M	$-191M	$-24M	$67M		$-29M
2018	$74M	$-148M	$170M	$-13M	$61M		$-28M
2017	$96M	$-54M	$-26M	$-13M	$83M		$-28M
2016	$40M	$-11M	$-26M	$-13M	$27M		$-28M
2015	$44M	$-18M	$-34M	$-16M	$28M		$-27M

Cash Flow Trends

A Piotroski F‑Score of 6 out of 9 reflects solid accounting fundamentals—positive operating cash flow trends and improving asset turnover—but indicates room for improvement in leverage and margin efficiency.
The Altman Z‑score of 3.89 places Azenta well within the ‘safe zone’ (>2.99), signaling a low probability of bankruptcy over the next two years despite modest free cash flow generation.
Combined, the Piotroski and Altman metrics suggest that while the balance sheet is structurally sound, the company must enhance cash conversion efficiency to sustain long‑term financial health.

Balance Sheet & Cash Flow Health

Azenta, Inc. (AZTA) — FCF & Capital Returns

Free Cash Flow Statistics

Buyback & Dividend Trends

A Piotroski F‑Score of 6 out of 9 reflects solid accounting fundamentals—positive operating cash flow trends and improving asset turnover—but indicates room for improvement in leverage and margin efficiency.
The Altman Z‑score of 3.89 places Azenta well within the ‘safe zone’ (>2.99), signaling a low probability of bankruptcy over the next two years despite modest free cash flow generation.
Combined, the Piotroski and Altman metrics suggest that while the balance sheet is structurally sound, the company must enhance cash conversion efficiency to sustain long‑term financial health.

Executive Insights & Key Takeaways

Key Takeaways

1Y Return

▼ -20.7%

vs S&P -44.4pp

Revenue 3Y CAGR

▲ +2.2%

5Y: +8.9%

Net Margin

-9.4%

▲ 3Y ago: -77.2%

ROIC

-0.8%

▲ 3Y ago: -0.8%

FCF Margin

6.5%

▲ 3Y ago: -97.8%

Piotroski

6/9

Moderate

Azenta, Inc. (AZTA) has underperformed sharply, delivering a -20.7% total return over the past year and a compounded annual loss of -19.5% over three years, far lagging the S&P 500 by 44.4% on an excess basis. The revenue base is modest at $594 M with only a 3.6% YoY increase and a 2.2% 3‑year CAGR, while gross margins sit at 45.5% but operating income remains negative (-1.9%) and net margins are deeply in the red (-9.4%), reflecting ongoing profitability challenges. Nonetheless, the balance sheet is relatively strong: a current ratio of 2.98 and a low debt‑to‑equity of 0.06 indicate ample liquidity and minimal leverage risk, complemented by an Altman Z‑score of 3.9 that signals financial safety. However, cash conversion is weak, with a cash conversion cycle of 158 days and operating cash flow covering only -129% of net income, suggesting the firm relies heavily on external financing to sustain operations. The combination of poor equity returns, thin profitability, but solid liquidity creates a mixed investment thesis where upside hinges on turning earnings positive while downside risk stems from cash flow fragility.

✅ Strengths

Low leverage (D/E 0.06) and a robust current ratio (2.98) give Azenta ample financial flexibility to invest in growth initiatives without risking solvency.
Gross margin of 45.5% demonstrates that the core business model can generate healthy contribution after direct costs, providing a foundation for scaling profitability if operating expenses are contained.
Institutional ownership is high at 116.1%, indicating confidence from professional investors and potentially limiting stock volatility through steady demand.

⚠️ Risks

Total return of -20.7% YTD and a 44.4% underperformance versus the S&P 500 highlight severe market sentiment risk that could depress future capital raising ability.
Negative operating margin (-1.9%) and net margin (-9.4%) show the company is still losing money on each dollar of sales, risking further erosion of equity value if earnings do not turn positive.
Cash conversion cycle of 158 days and OCF/NI of -129% reveal that Azenta is generating insufficient operating cash to cover its losses, creating reliance on external financing and heightening liquidity risk.

AZTA

Related Reports

Visit finexus.net/reports for Valuation, Return & Risk, and other reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.